EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access

A 5:2 Intermittent Fasting Meal Replacement Diet and Glycemic Control for Adults With Diabetes

Lixin Guo, Yue Xi, Wenbo Jin, Huijuan Yuan, Guijun Qin, Shuchun Chen, Lihui Zhang, Yu Liu, Xingbo Cheng, Wen Liu, Dongni Yu

JAMA Network Open · 21.06.2024 · 7 (6) · e2416786

DOI: 10.1001/jamanetworkopen.2024.16786 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JAMA Network Open, online erschienen am 21.06.2024. Verfasst von Lixin Guo und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, …. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Fasting, Metformin, Glucosides. Die Arbeit wurde bisher 69-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance An intermittent fasting plan consisting of 2 nonconsecutive fasting days and 5 days of habitual intake per week and meal replacement diet (5:2 MR) could provide additional benefits to patients with type 2 diabetes.

Objective

To evaluate the effect of the 5:2 MR on glycemic control among patients with early type 2 diabetes compared with metformin and empagliflozin. Design, Setting, and Participants The EARLY (Exploration of Treatment of Newly Diagnosed Overweight/Obese Type 2 Diabetes Mellitus) study is a randomized, open-label, active parallel-controlled clinical trial conducted between November 13, 2020, and December 29, 2022, in 9 centers across China. A total of 509 eligible patients underwent screening, out of which 405 were randomly assigned to 3 groups and included in the intention-to-treat analysis.

Interventions

Patients were randomly allocated in a 1:1:1 ratio to receive either metformin, empagliflozin, or 5:2 MR. The treatment was 16 weeks, with an 8-week follow-up. Main Outcomes and Measures The primary end point was the change in hemoglobin A 1c (HbA 1c ) level from baseline to 16 weeks. Secondary end points included changes in body weight, anthropometric measurements, and biochemical parameters.

Results

Of the 405 randomized participants (265 men [65.4%]; mean [SD] age, 45.5 [11.0] years; mean [SD] body mass index, 29.5 [4.1]; and mean [SD] HbA 1c level, 7.9% [0.6%]), 332 completed the 16-week treatment. From baseline to week 16, participants in the 5:2 MR group showed the greatest reduction in HbA 1c (least-squares mean [LSM], −1.9% [SE, 0.2%]), significantly greater than patients receiving metformin (LSM, −1.6% [SE, 0.2%]; adjusted LSM difference, −0.3% [95% CI, −0.4% to −0.1%]) and empagliflozin (LSM, −1.5% [SE, 0.2%]; adjusted LSM difference, −0.4% [95% CI, −0.6% to −0.2%]). At week 16, the mean weight loss in the 5:2 MR group (LSM, −9.7 kg [SE, 2.2 kg]) was greater than that in the metformin group (LSM, −5.5 kg [SE, 2.3 kg]) and empagliflozin group (LSM, −5.8 kg [SE, 2.3 kg]). Conclusions and Relevance This randomized clinical trial of Chinese adults with overweight or obesity and with early type 2 diabetes found that 5:2 MR could improve glycemic outcomes and weight loss in the short term compared with metformin or empagliflozin, making it a promising initial intervention and early management for type 2 diabetes. Trial Registration Chinese Clinical Trial Registry Identifier: ChiCTR2000040656

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2FastingMetforminGlucosidesBenzhydryl CompoundsGlycemic ControlHumansMaleFemaleMiddle AgedAdultGlycated HemoglobinHypoglycemic AgentsChinaBlood GlucoseIntermittent Fasting

Substanzen

MetforminGlucosidesempagliflozinBenzhydryl CompoundsGlycated HemoglobinHypoglycemic AgentsBlood Glucose

Autor:innen und Institutionen

  • Department of Endocrinology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
  • Department of Endocrinology, The Third Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning, China.
  • Department of Endocrinology, Nanyang Central Hospital, Nanyang, Henan, China.
  • Department of Endocrinology, Henan Provincial People's Hospital, Zhengzhou, Henan, China.
  • Department of Endocrinology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
  • Department of Endocrinology, Hebei Provincial People's Hospital, Shijiazhuang, Hebei, China.

Zitieren

APA

Guo, L., Xi, Y., Jin, W., Yuan, H., Qin, G., Chen, S., Zhang, L., Liu, Y., Cheng, X., Liu, W., & Yu, D. (2024). A 5:2 Intermittent Fasting Meal Replacement Diet and Glycemic Control for Adults With Diabetes. JAMA Network Open, 7(6), e2416786. https://doi.org/10.1001/jamanetworkopen.2024.16786

Vancouver

Guo L, Xi Y, Jin W, Yuan H, Qin G, Chen S, et al. A 5:2 Intermittent Fasting Meal Replacement Diet and Glycemic Control for Adults With Diabetes. JAMA Network Open. 2024;7(6):e2416786. doi:10.1001/jamanetworkopen.2024.16786

BibTeX
@article{Guo2024,
  author = {Guo, Lixin and Xi, Yue and Jin, Wenbo and Yuan, Huijuan and Qin, Guijun and Chen, Shuchun and Zhang, Lihui and Liu, Yu and Cheng, Xingbo and Liu, Wen and Yu, Dongni},
  title = {A 5:2 Intermittent Fasting Meal Replacement Diet and Glycemic Control for Adults With Diabetes},
  journal = {JAMA Network Open},
  year = {2024},
  volume = {7},
  number = {6},
  pages = {e2416786},
  doi = {10.1001/jamanetworkopen.2024.16786}
}
Kostenlos starten →